Panel to Discuss Amylyx NDA for ALS

Federal Register notice: FDA has announced a 3/30 Peripheral and Central Nervous System Drugs Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. Panel members are scheduled to discuss an Amylyx Pharmaceuticals NDA for sodium phenylbutyrate/taurursodiol (AMX0035) powder for oral suspension, indicated for treating amyotrophic lateral sclerosis. To view the notice, click here.

Read more